Skip to main content

Table 2 Comparison of patient background characteristics between a TNFi insensitivity group and a poor response group. For each variable, p values of a simple comparison between the two groups using chi-squared test are shown

From: Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study

Category

TNIi insensitivity

Refractory

Control

p value*

N

%

N

%

N

%

P1

P2

P3

Gender

Female

75

79.8

501

82.9

731

79.9

0.83

0.14

0.34

Male

19

20.2

103

17.1

184

20.1

Age group

≦50

23

24.5

129

21.4

228

24.9

0.62

0.41

0.48

51–60

26

27.7

149

24.7

205

22.4

61–70

19

20.2

165

27.3

246

26.9

71

26

27.7

161

26.7

236

25.8

Disease duration (year)

< 0.5

22

23.4

75

12.4

165

18.0

0.45

< 0.01†

0.01†

0.5–2

31

33.0

163

27.0

284

31.0

2–5

17

18.1

117

19.4

159

17.4

≥ 5

24

25.5

247

40.9

306

33.4

DAS28-CRP at week 0

< 3.2

3

3.2

6

1.0

43

4.7

< 0.01†

< 0.01†

0.18

3.2–5.1

12

12.8

94

15.6

259

28.3

> 5.1

79

84.0

502

83.1

613

67.0

RF positivity**

Negative

25

26.6

127

21.0

240

26.2

0.95

0.02†

0.24

Positive

69

73.4

473

78.3

673

73.6

Use of GC

No

66

70.2

393

65.1

708

77.4

0.13

< 0.01†

0.30

Yes

28

29.8

211

34.9

207

22.6

Dose of MTX (mg/week)

0

13

13.8

81

13.4

83

9.1

0.22

< 0.01†

0.47

1–6

10

10.6

74

12.3

79

8.6

7–9

22

23.4

189

31.3

218

23.8

10–15

32

34.0

176

29.1

294

32.1

> 15

17

18.1

84

13.9

241

26.3

Failure in > 2 csDMARDs

No

44

46.8

301

49.8

365

39.9

0.16

< 0.01†

0.66

Yes

50

53.2

303

50.2

550

60.1

Entry phase

I

29

30.9

287

47.5

327

35.7

0.11

< 0.01†

< 0.01†

II

24

25.5

169

28.0

179

19.6

III

22

23.4

95

15.7

287

31.4

Drug type

IFX

2

2.1

11

1.8

12

1.3

0.77

< 0.01†

< 0.01†

ETN

17

18.1

42

7.0

110

12.0

ADA

5

5.3

55

9.1

55

6.0

GLM

22

23.4

234

38.7

186

20.3

CZP

67

71.3

315

52.2

674

73.7

  1. *P1, comparison between control and insensitivity; P2, comparison between control and refractory; P3, comparison between insensitivity and refractory
  2. **RF > 20 IU/mL was defined as positive
  3. †p < 0.05
  4. DAS28 disease activity score for 28 joints, CRP c-reactive protein, MTX methotrexate, IFX infliximab, ETA etanercept, ADA adalimumab, GLM golimumab, CZP certolizumab, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs